Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Myopic maculopathy is the leading cause of subfoveal choroidal neovascularization (CNV) among patients under 50 years of age. New antiangiogenic drugs are being used off-label to treat myopic CNV and the short-term outcome of these therapies has been reported. The aim of this study is to report the changes in best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) in highly myopic CNV treated by intravitreal bevacizumab at 2 years.

Methods

Prospective non-randomized, interventional case series study of 19 highly myopic eyes from 18 patients with subfoveal and juxtafoveal CNV treated by three monthly intravitreal injections of 1.25 mg bevacizumab. Patients were evaluated for BCVA and OCT at baseline and then monthly for 2 years.

Results

Eleven eyes were naive for treatment and eight eyes had been previously treated by photodynamic therapy. LogMAR BCVA averaged 0.54 (SD 0.25, range 0.2–1.0; Snellen 20/69) at baseline; 0.40 (SD 0.35, range 0.0–1.2; Snellen 20/50) at 1 year; and 0.47 (SD 0.31, range 0.0–1.0; Snellen 20/59) at 2 years (p = 0.04 and p = 0.20, respectively, Student's t test paired data). Re-treatment was performed in four eyes during the first year: three eyes at month six and one eye at month 12. Four eyes required one re-injection during the second year at months 14, 18, 20, and 24. Neither ocular nor systemic adverse reactions were detected.

Conclusions

Intravitreal bevacizumab seems to be effective for subfoveal and juxtafoveal CNV in highly myopic eyes. BCVA gain decreases and is no longer significant by the end of the second year.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241–1244

    CAS  PubMed  Google Scholar 

  2. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91:157–160

    Article  PubMed  Google Scholar 

  3. Tewari A, Dhalla MS, Apte RS (2006) Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26:1093–1094

    Article  PubMed  Google Scholar 

  4. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y (2007) Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91:161–165

    Article  CAS  PubMed  Google Scholar 

  5. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez-Lopez F, Rodriguez M, Fernandez M (2009) Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye 23:334–338

    Article  CAS  PubMed  Google Scholar 

  6. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368–1370

    Article  CAS  PubMed  Google Scholar 

  7. Mandal S, Venkatesh P, Sampangi R, Garg S (2007) Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17:620–626

    CAS  PubMed  Google Scholar 

  8. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960–963

    Article  PubMed  Google Scholar 

  9. Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114:2190–2196

    Article  PubMed  Google Scholar 

  10. Arias L, Planas N, Prades S, Caminal JM, Rubio M, Pujol O, Roca G (2008) Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 92:1035–1039

    Article  CAS  PubMed  Google Scholar 

  11. Wu PC, Chen YJ (2009) Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye

  12. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S (2009) Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 93:448–451

    Article  CAS  PubMed  Google Scholar 

  13. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y (2009) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147(94–100):e101

    Google Scholar 

  14. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB (2009) Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147(84–93):e81

    Google Scholar 

  15. Chan WM, Lai TY, Liu DT, Lam DS (2009) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 93:150–154

    Article  PubMed  Google Scholar 

  16. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141:456–462

    Article  CAS  PubMed  Google Scholar 

  17. Bennett MD, Yee W (2007) Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol 245:903–905

    Article  PubMed  Google Scholar 

  18. Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosaa A, Carvalheira F, Abreu JR, Cunha-Vaz JG (2008) Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 28:1117–1123

    Article  PubMed  Google Scholar 

  19. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A (2009) Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:311–318

    Article  CAS  PubMed  Google Scholar 

  20. Figurska M, Stankiewicz A (2008) Anty-VEGF therapy in the treatment of myopic macular choroidal neovascularization–cases report. Klin Oczna 110:387–391

    PubMed  Google Scholar 

  21. Ruiz-Moreno JM, Amat P, Montero JA, Lugo F (2008) Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years’ outcome. Br J Ophthalmol 92:792–794

    Article  CAS  PubMed  Google Scholar 

  22. Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, Takahashi K, Uchihori Y, Gomi F (2009) Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 149:140–146

    Google Scholar 

  23. Krebs I, Binder S, Stolba U, Glittenberg C, Brannath W, Goll A (2005) Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 140:416–425

    PubMed  Google Scholar 

  24. Ruiz-Moreno JM, Montero JA (2003) Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 87:856–859

    Article  CAS  PubMed  Google Scholar 

  25. Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S (2009) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularization. Br J Ophthalmol. doi:10.1136/bjo.2009.166025

  26. Ruiz-Moreno JM, Montero JA (2002) Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 12:117–122

    CAS  PubMed  Google Scholar 

  27. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19:361–372

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors have full control of all primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested. This study was supported in part by a grant of the Spanish Ministry of Health, Instituto de Salud Carlos III, Red Temática de Investigación Cooperativa en Salud “Patología ocular del envejecimiento, calidad visual y calidad de vida” (RD07/0062/0019). The design of this study was reviewed and approved by the clinical ethics committee at Vissum Ophthalmological Institute of Alicante. Written informed consent and individualized approval from the National Ministry of Health was obtained prior to the procedure. This study has been performed in accordance with the ethical standards of the 1964 Declaration of Helsinki, and data gathering was performed after obtaining written informed consent. Patients were informed about the off-label situation of this therapy and women of child-bearing age were also informed about the possible risks of pregnancy and in utero exposition.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Castilla La Mancha University, Albacete, Spain

    Jose M. Ruiz-Moreno

  2. Alicante Institute of Ophthalmology, VISSUM, Vitreo-Retinal Unit, Alicante, Spain

    Jose M. Ruiz-Moreno & Javier A. Montero

  3. Pío del Río Hortega University Hospital, Ophthalmology Unit, Valladolid, Spain

    Javier A. Montero

  4. Departamento de Ciencias Médicas. Facultad de Medicina, Avda de Almansa, 14, 02006, Albacete, Spain

    Jose M. Ruiz-Moreno

Authors
  1. Jose M. Ruiz-Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier A. Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose M. Ruiz-Moreno.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruiz-Moreno, J.M., Montero, J.A. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 248, 937–941 (2010). https://doi.org/10.1007/s00417-010-1340-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-010-1340-y

Keywords

Search

Navigation